Novartis Gene Therapies, Inc. et al. vs. Genzyme Corporation et al.

Explore the PTAB proceeding IPR2023-00608 filed by Novartis Gene Therapies, Inc. et al. on 2023-02-22. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2023-00608

Filing Date

2023-02-22

Accorded Filing Date

2023-02-22

Institution Decision Date

2023-08-30

Last Modified Date

—

Proceeding Type

IPR

Termination Date

2023-08-30

Trial Status

Institution Denied

Parties & Counsel

Petitioner

Novartis Gene Therapies, Inc. et al.

Represented By

Livingstone, Johnet al

Patent Owner / Respondent

Genzyme Corporation et al.

Represented By

Antons, Amandaet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 12661553

Respondent Patent Number 9051542

External Links

Espacenet

Google Patents

Respondent Inventor John Fraser Wright et al

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

40 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name LISA P. RASMUSSEN - SANOFI

Customer Number 5487

Address 450 WATER STREET, Cambridge, MA, 02141, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
36844	Joseph Kirk Jr	908-981-6911
39150	John Conway	908-981-6688
40564	Anne Collins	978-341-0036
44045	Sandra Brockman-Lee	857-523-9199
45736	Pamela Torpey	508--27-1-0683
45979	Milan Vinnola	619-238-0062
47150	Nicole Parsons	617-685-5697
52610	Kelly Bender	2485930581
54154	Allyson Hatton	508-361-7392
54958	Janann Ali	617-685-5645
58163	Alejandro Martinez	617-685-5935
59682	Jeremy Bond	617-685-5653
61358	Ryan Mcquade	617-838-5595
61393	Isaac Hubner	617-866-4544
62108	Siew Chong	973-980-0397
63001	Stephanie Donahue	908-331-4406
63750	Mayssam Ali	617-685-5646
64259	Xuemei Peng	908-981-6951
64740	Alan Townsley	202-857-2278
64828	Jeffrey Weber	617-685-6431
66863	Patricia Callanan	617-866-4404
67265	Yi Wang	617-685-5735
67340	Dhruv Kaushal	617-245-4065
68308	Jonathan Andron	617-685-5658
68315	Meenakshy Chakravorty	781-418-9211
69032	Robert Bolcome Iii	857-331-1597
69052	Jing Wang	617-951-8720
69953	Janet Tse	617-564-6571
70740	Erika Wallace	617-937-1397
71226	Meghan Klaric	313-465-7211
72110	Daniel Tate	800-981-2491
72475	Indrani Dasgupta	617-685-5977
72868	David Lefebvre	617-685-5338
72919	Ted Ririe	385-312-6536
74124	Evan King	781-234-4286
75427	Shirley Tan	617-646-8444
77001	Sara Haines	003-348-1492783
80264	Christopher Marion	314-517-7022
80424	Victoria Pedanou	508-736-4409
81386	Erin May	617-251-9709

Proceeding Documents

Notice: refund approved NOTICE

2023-10-06 FILING PARTY: BOARD

Download

'542 Petitioner's Request for Refund OTHER

2023-10-04 FILING PARTY: PETITIONER

Download

Denying Institution of Inter Partes Review 35 U.S.C. § 314 DECISION

2023-08-30 FILING PARTY: BOARD

Download

'542 Petitioner's Updated Exhibit List NOTICE

2023-08-23 FILING PARTY: PETITIONER

Download

1031

Novartis Exhibit 1031_263 Memorandum Opinion Markman Exhibit

2023-08-23 FILING PARTY: PETITIONER

Download

Novartis Gene Therapies, Inc. et al. vs. Genzyme Corporation et al.

Proceeding Overview

Parties & Counsel

Petitioner

Novartis Gene Therapies, Inc. et al.

Represented By

Patent Owner / Respondent

Genzyme Corporation et al.

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Notice: refund approved NOTICE

'542 Petitioner's Request for Refund OTHER

Denying Institution of Inter Partes Review 35 U.S.C. § 314 DECISION

'542 Petitioner's Updated Exhibit List NOTICE

Novartis Exhibit 1031_263 Memorandum Opinion Markman Exhibit

Patent Owner's Surreply to Petitioner's Reply to Patent Owner's Preliminary Response OTHER

Novartis Exhibit 1030_Sotera Stipulation Exhibit

July 11, 2023 Teleconference Transcript Exhibit

'542 Petitioner's Reply to Patent Owner's Preliminary Response OTHER

Patent Owner Genzyme's Notice of Filing Exhibit: Teleconference Transcript of July 11, 2023 NOTICE

CV of Martyn Davis Exhibit

Statutory Disclaimer Exhibit

Patent Owner's Preliminary Response POPR

Time to Trial 2 Exhibit

XIE-Large_Scale_Production Exhibit

Time to Trial Exhibit

KONZ-Develpment_of_a_Purification Exhibit

Order Denying Motion to Amend Exhibit

Stip & Order to Amend Case Schedule Exhibit

Declaration of Martyn C. Davies Exhibit

Defendant's First Amended Invalidity Contentions Exhibit

Patent Owner's Response to Novartis's Notice Regarding Multiple Petitions RESPONSE

Wright - Identification_of_Factors Exhibit

SMITH-Gene_Therapy Exhibit

Granting Patent Owner Unopposed Motion for Admission Pro Hac Vice of Katherine A. Helm 37 C.F.R. § 42.10 ORDER

Declaration of Katherine A. Helm J.D., PH.D. In Support of Motion for Admission Pro Hac Vice Exhibit

Patent Owner Genzyme Corporation's Unopposed Motion For Pro Hac Vice Admission of Katherine A. Helm, J.D., PH.D. MOTION

Patent Owner's Updated Power of Attorney NOTICE

Patent Owner's Updated Mandatory Notices NOTICE

Petitioners’ Updated Mandatory Notices NOTICE

Petitioners’ Corrected Exhibit List OTHER

Notice : Power of Attorney NOTICE

Notice: Notice filing date accorded NOTICE

Notice : Mandatory Notice NOTICE

Novartis Exhibit 1029_Utility Patent Application for 11,141,996 Exhibit

Novartis Exhibit 1014_ABOUT_ definition in the Cambridge English Dictionary Exhibit

Novartis Exhibit 1011_Potter 2002 Exhibit

Novartis Exhibit 1017_FDA 2005 Guidance Exhibit

’542 Petitioners’ Exhibit List NOTICE

Novartis Exhibit 1006_Mingozzi 2002 Exhibit

Petition for Inter Partes Review of U.S. Patent No. 9,051,542 PETITION

Novartis Exhibit 1016_Freireich 1966 Exhibit

'542 Petitioners’ Power of Attorney NOTICE

Novartis Exhibit 1007_Wright Exhibit

Novartis Exhibit 1026_USP 6146874 Exhibit

Novartis Exhibit 1008_Gatlin_Injectable Drug Development Exhibit

Novartis Exhibit 1002_Prosecution History of USP 9051542 Exhibit

Novartis Exhibit 1025 Declaration of Dr. Mansoor Amiji_IPR2023-00608 Exhibit

Novartis Exhibit 1019_Johnson 1975 Exhibit

Novartis Exhibit 1013_Croyle Exhibit

Novartis Exhibit 1010_Lochrie PCT WO 03046142A2 Exhibit

Novartis Exhibit 1018_Carpenter 2002 Exhibit

Novartis Exhibit 1009_Liu PCT_WO 03 039459A2 Exhibit

Novartis Exhibit 1005_Huang 2000 Exhibit

Novartis Exhibit 1015_USP 6261823 Exhibit

Novartis Exhibit 1004_Frei PCT_WO 99 41416A2 Exhibit

Novartis Exhibit 1001_USP 9051542 Exhibit

Novartis Exhibit 1024_Common Buffers and Stock Solutions Exhibit

Novartis Exhibit 1021_Remington Volume II Exhibit

Novartis Exhibit 1003_Evans PCT_WO 01_66137 Exhibit

Petitioners’ Explanation of Multiple Petitions OTHER

Novartis Exhibit 1028_Pub. No. 2002 0041884A1 Exhibit

Novartis Exhibit 1022_Handbook of Pharmaceutical Excipients Exhibit

Novartis Exhibit 1012_Clark 2002 Exhibit

Novartis Exhibit 1023_2023.01.24 DI 105 Joint Claim Const. Brief-Public Exhibit